Xenon Pharmaceuticals announced the results of a late-stage clinical trial of its drug to treat a common type of seizure disorder. The drug significantly reduced the frequency of seizures in patients compared to placebo. A study has shown the strong effectiveness of this seizure medicine. The results confirm that the treatment is effective in reducing the number of seizures. These findings are from an advanced phase of the trial.